Silence Therapeutics plc
For the period ended Jun 30, 2026. Filed Aug 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
9. Shareholders’ equity
| June 30, 2026 | December 31, 2025 | |
|---|---|---|
| Authorized, allotted, called up and fully paid ordinary shares, par value £0.05 | 10,292 | 10,290 |
| Number | Number | |
| Number of shares in issue | 141,739,180 | 141,701,848 |
| Number of equivalent ADSs in issue | 47,246,393 | 47,233,949 |
The Group has only one class of shares. All ordinary shares have equal voting rights and rank pari passu for the distribution of dividends.
In March 2026, the Company entered into an Open Market Sale Agreement, or the Sales Agreement, with Jefferies LLC, or Jefferies, as sales agent, pursuant to which the Company may offer and sell, from time to time through Jefferies, at its option, its ordinary shares. The Company agreed to pay Jefferies a commission of up to 3.0% of the aggregate gross proceeds for the ordinary shares sold through the Sales Agreement. During the three months ended June 30, 2026, no sales were made under the Sales Agreement.
Details of the shares issued during the current three months and prior year are as follows:
| Number of shares in issue at January 1, 2025 | 141,674,074 |
|---|---|
| Number of ADSs in issue at January 1, 2025 | 47,224,691 |
| Shares issued during the year | |
| Options exercised at $0.20/ADS or $0.07/ordinary share | 17,775 |
| Options exercised at $4.23/ADS or $1.41/ordinary share | 9,999 |
| Number of shares in issue at December 31, 2025 | 141,701,848 |
| Number of equivalent ADSs in issue at December 31, 2025 | 47,233,949 |
| Number of shares in issue at January 1, 2026 | 141,701,848 |
| Number of ADSs in issue at January 1, 2026 | 47,233,949 |
| Options exercised at $0.20/ADS or $0.07/ordinary share | 7,491 |
| Options exercised at $4.48/ADS or $1.49/ordinary share | 8,838 |
| Options exercised at $7.19/ADS or $2.40/ordinary share | 21,000 |
| Options exercised at $9.98/ADS or $3.33/ordinary share | 3 |
| Number of shares in issue at June 30, 2026 | 141,739,180 |
| Number of equivalent ADSs in issue at June 30, 2026 | 47,246,393 |
The Group has outstanding ADSs and each ADS represents three ordinary shares.
- Equity-settled share-based compensation
The Group has issued share options under the 2023 Equity Incentive Plan, or 2023 Plan, 2018 Long Term Incentive Plan, or LTIP, 2018 Non-Employee Long Term Incentive Plan, or Non-Employee LTIP, and individual share option contracts, each of which is or was open to all eligible service providers of the Group. Under the 2023 Plan, the LTIP, Non-Employee LTIP, and individual contracts the options typically vest after three years, with the exception of some options granted to certain members of key management personnel which have longer vesting periods. The vesting period for these options ranges from 3 to 48 months. The vested options usually lapse less than one year following the employee or service provider leaving the Group.
| Number ofADSs | WeightedAverageExerciseprice | |
|---|---|---|
| $ | ||
| Options | ||
| Outstanding at January 1, 2026 | 6,961,366 | |
| Granted during the period | 1,104,085 | |
| Lapsed or forfeited during the period | (364,918) | |
| Exercised during the period | (12,444) | |
| Outstanding at June 30, 2026 | 7,688,089 | $12.61 |
| Exercisable at the period-end | 4,794,137 | |
The table above shows the number of options in relation to ordinary shares and equivalent ADSs outstanding and exercisable at period end, on the conversion ratio of three ordinary shares to one ADS.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.